Diseases Cached

Kala-azar: Symptoms, Treatments, Medications and Prevention

by · Published · Updated

Kala-azar, also known as visceral leishmaniasis, is a severe parasitic disease caused by protozoan parasites of the genus Leishmania, specifically Leishmania donovani and Leishmania infantum. The disease is transmitted to humans through the bite of infected female phlebotomine sandflies. Kala-azar is the second largest parasitic killer in the world, after malaria, and is characterized by fever, weight loss, spleen and liver enlargement, and anemia. Without treatment, kala-azar is almost always fatal, making it one of the most dangerous neglected tropical diseases (NTDs).

What is Kala-azar?

Kala-azar, or visceral leishmaniasis, is a systemic disease that affects internal organs, primarily the spleen, liver, and bone marrow. It is caused by protozoan parasites from the Leishmania genus, which are transmitted to humans by the bite of an infected female sandfly (Phlebotomus or Lutzomyia species). The disease can be divided into three major clinical forms:

  • Visceral Leishmaniasis (VL): The most severe form, commonly known as kala-azar, affects the internal organs.
  • Cutaneous Leishmaniasis (CL): Affects the skin and is the most common form.
  • Mucocutaneous Leishmaniasis (MCL): Affects the mucous membranes of the nose, mouth, and throat.

Kala-azar, the visceral form, is the most dangerous type of leishmaniasis and is primarily found in regions where the disease is endemic, particularly in parts of Asia, East Africa, and South America.

Transmission of Kala-azar

The Leishmania parasites are transmitted through the bite of infected female sandflies. When the sandfly bites a human to feed on blood, the parasites enter the bloodstream and migrate to the internal organs, where they multiply in large numbers. Sandflies are most active in the evening and at night, making people who are outside during these hours more vulnerable to infection.

Once inside the human body, the parasites invade macrophages (a type of immune cell) and replicate, leading to systemic infection. The incubation period of the disease can range from a few weeks to several months, and without prompt treatment, it can cause death due to complications such as secondary infections, hemorrhage, or severe anemia.

Who is at Risk of Kala-azar?

Certain populations are at higher risk of contracting kala-azar due to environmental, social, and biological factors. The disease is most common in tropical and subtropical regions, particularly in areas with poor socioeconomic conditions and limited access to healthcare.

High-Risk Populations

1. People Living in Endemic Areas

The highest risk group for kala-azar includes people living in regions where Leishmania parasites and sandflies are endemic. These areas are typically rural, forested, or semi-urban regions in tropical and subtropical zones where sandflies thrive. Countries with the highest incidence of kala-azar include India, Sudan, South Sudan, Ethiopia, Brazil, and Bangladesh.

2. Children and Immunocompromised Individuals

Children and individuals with weakened immune systems, such as those with HIV/AIDS, malnutrition, or other immunosuppressive conditions, are at an increased risk of developing severe kala-azar. These groups are less able to fight off the infection, leading to a higher likelihood of developing life-threatening complications.

3. Malnourished Individuals

Malnutrition is a significant risk factor for kala-azar. Poor nutrition weakens the immune system, making it harder for the body to mount a defense against the parasite. People living in areas with high levels of food insecurity are particularly vulnerable to developing severe forms of the disease.

4. Travelers to Endemic Regions

Although most cases of kala-azar occur in people living in endemic regions, travelers to these areas are also at risk, particularly if they engage in activities that increase their exposure to sandfly bites, such as hiking, camping, or staying outdoors in the evening and night. Travelers to regions with known outbreaks or where the disease is endemic should take precautions to avoid sandfly bites.

5. Agricultural and Construction Workers

People who work outdoors in rural areas, such as agricultural laborers or construction workers, are at an increased risk of kala-azar due to their constant exposure to sandflies. Sandflies breed in humid and dark areas, making workers who spend time near forests, caves, or areas with abundant vegetation more vulnerable.

6. People Living in Poor Housing Conditions

Kala-azar disproportionately affects people living in poor, overcrowded, and unsanitary conditions. Housing with cracks in walls, thatched roofs, and mud floors provides an ideal habitat for sandflies to breed and rest during the day. Inadequate sanitation and water infrastructure also contribute to the spread of the disease.

Symptoms of Kala-azar

The symptoms of kala-azar typically develop gradually over weeks to months after the initial infection. The disease progresses through two main stages: early symptoms and advanced-stage symptoms. If untreated, the disease can lead to death, but early diagnosis and treatment can significantly improve outcomes.

Early Symptoms

In the initial stages of kala-azar, symptoms are often non-specific and resemble those of other common tropical diseases, such as malaria or tuberculosis. These early symptoms include:

1. Fever

  • Intermittent or persistent fever is the most common symptom of kala-azar. The fever may be high and often occurs in irregular spikes.
  • Unlike malaria, the fever in kala-azar is not necessarily associated with chills or sweating.

2. Fatigue and Weakness

  • People with kala-azar often experience extreme fatigue, weakness, and lethargy. This is partly due to the parasitic infection and partly due to the resulting anemia.

3. Weight Loss

  • Significant and rapid weight loss is a hallmark symptom of kala-azar. Affected individuals may appear emaciated, despite maintaining a normal or increased appetite in the early stages.

4. Loss of Appetite

  • Loss of appetite is common, particularly as the disease progresses. This symptom contributes to the rapid weight loss experienced by patients.

Advanced-Stage Symptoms

As the disease progresses without treatment, it leads to more severe systemic involvement, with the parasites spreading to the liver, spleen, and bone marrow.

1. Splenomegaly (Enlarged Spleen)

  • Splenomegaly, or an enlarged spleen, is one of the defining features of kala-azar. The spleen becomes grossly enlarged and can be felt through the abdomen.
  • The enlarged spleen is often painless but may cause discomfort or a feeling of fullness in the abdomen.

2. Hepatomegaly (Enlarged Liver)

  • The liver also enlarges as the parasites spread, a condition known as hepatomegaly. This can lead to pain or discomfort in the upper right quadrant of the abdomen.
  • Both hepatomegaly and splenomegaly can lead to abdominal distension and discomfort.

3. Anemia

  • Anemia is a prominent feature of kala-azar due to the destruction of red blood cells, suppression of bone marrow function, and increased demand for iron by the body.
  • Anemia leads to symptoms such as pale skin, dizziness, shortness of breath, and fatigue.

4. Darkening of the Skin

  • The name “kala-azar” means “black fever” in Hindi, referring to the darkening of the skin that may occur in some patients with advanced disease. This hyperpigmentation is more common in individuals with darker skin tones and typically affects the face, hands, and abdomen.

5. Frequent Infections

  • Kala-azar weakens the immune system, making affected individuals more susceptible to secondary bacterial and viral infections, such as pneumonia and tuberculosis.
  • Infections can further complicate the disease and contribute to its high mortality rate in untreated cases.

6. Swelling of the Lymph Nodes

  • In some cases, kala-azar can cause swelling of the lymph nodes, particularly in the cervical (neck) region.

7. Bleeding Disorders

  • As the disease progresses, patients may develop bleeding disorders, such as nosebleeds, gum bleeding, and petechiae (small red or purple spots caused by bleeding under the skin). This is due to thrombocytopenia (low platelet count) and other coagulation abnormalities.

Post-Kala-azar Dermal Leishmaniasis (PKDL)

In some individuals, particularly in regions such as India and Sudan, kala-azar can lead to a condition known as post-kala-azar dermal leishmaniasis (PKDL). PKDL typically occurs months to years after successful treatment of visceral leishmaniasis and presents with skin lesions, including papules, nodules, or depigmented macules. While not life-threatening, PKDL can cause significant cosmetic disfigurement and is important because patients with PKDL can serve as reservoirs of the parasite, potentially contributing to the spread of the disease.

Diagnosis of Kala-azar

Diagnosing kala-azar can be challenging, particularly in regions where other tropical diseases, such as malaria, are prevalent and share similar symptoms. Early diagnosis is crucial to prevent complications and initiate prompt treatment.

Clinical Evaluation

The first step in diagnosing kala-azar is a thorough clinical evaluation. Healthcare providers will ask about the patient’s symptoms, history of travel or residence in an endemic area, and any potential exposure to sandflies. Key clinical signs such as fever, splenomegaly, hepatomegaly, and weight loss will raise suspicion of visceral leishmaniasis.

Laboratory Tests for Kala-azar

Several diagnostic tests are available to confirm the diagnosis of kala-azar, each with its advantages and limitations. These tests are used to detect the presence of Leishmania parasites or the body’s immune response to the infection.

1. Direct Parasitological Diagnosis

Direct demonstration of Leishmania parasites in tissue samples remains the gold standard for diagnosing kala-azar.

  • Splenic/Bone Marrow/Aspirate Smear: A tissue sample is taken from the spleen, bone marrow, or lymph nodes and stained for microscopic examination. The presence of amastigotes (the intracellular form of the parasite) confirms the diagnosis.
    • Advantages: High sensitivity.
    • Disadvantages: Invasive procedure, risk of complications, and requires skilled personnel.

2. Serological Tests

Serological tests detect antibodies produced by the immune system in response to Leishmania infection. These tests are widely used in resource-limited settings due to their ease of use.

  • rK39 Antigen-Based Rapid Diagnostic Test (RDT): This is a commonly used point-of-care test that detects antibodies to the rK39 antigen of Leishmania donovani. It is highly sensitive and specific for visceral leishmaniasis in endemic areas.
    • Advantages: Simple, non-invasive, and provides results in minutes.
    • Disadvantages: May produce false positives in individuals with previous exposure to Leishmania or other related diseases.

3. Polymerase Chain Reaction (PCR)

PCR is a molecular diagnostic technique that detects the DNA of Leishmania parasites in blood or tissue samples. PCR is highly sensitive and specific, making it useful for diagnosing kala-azar in cases where other tests are inconclusive.

  • Advantages: High sensitivity and specificity, can detect low parasite loads.
  • Disadvantages: Requires specialized equipment and technical expertise, making it less accessible in resource-poor settings.

4. Montenegro Skin Test (Leishmanin Test)

The Montenegro skin test, also known as the leishmanin test, is a delayed hypersensitivity test used to detect exposure to Leishmania parasites. However, it is not used for diagnosing active kala-azar, as the test is negative in individuals with visceral leishmaniasis and only becomes positive after treatment or recovery.

Imaging Studies

In some cases, imaging studies such as ultrasound or computed tomography (CT) scans may be used to assess the extent of organ involvement, particularly for evaluating splenomegaly or hepatomegaly. However, imaging is not typically used for routine diagnosis in resource-limited settings.

Treatments for Kala-azar

Treatment of kala-azar is essential to prevent death and reduce the risk of complications. The choice of treatment depends on several factors, including the severity of the disease, the geographical region, and the patient’s immune status. Treatment should be initiated as soon as possible to prevent the progression of the disease and its associated complications.

Antileishmanial Therapy

Several drugs are available to treat kala-azar, and the choice of drug depends on factors such as the geographical region, drug resistance patterns, and the patient’s condition. The main goal of treatment is to eliminate the parasite from the body and prevent relapse.

1. Sodium Stibogluconate (Pentostam)

Sodium stibogluconate, an antimonial drug, has been used for decades as the primary treatment for kala-azar in many regions. It is administered as an intramuscular or intravenous injection and is effective in most cases.

  • Dosage: Typically administered at a dose of 20 mg/kg/day for 28 to 30 days.
  • Mechanism of Action: Sodium stibogluconate interferes with the energy metabolism of the Leishmania parasite, leading to its death.
  • Side Effects: Sodium stibogluconate can cause significant side effects, including pancreatitis, liver toxicity, cardiac arrhythmias, and bone marrow suppression.

2. Amphotericin B (Liposomal Amphotericin B)

Liposomal amphotericin B is considered one of the most effective treatments for kala-azar, particularly in regions where resistance to antimonial drugs has emerged. It is preferred for its higher efficacy and lower toxicity compared to conventional amphotericin B.

  • Dosage: A single-dose regimen of 10 mg/kg is commonly used, although longer regimens may be required in some cases.
  • Mechanism of Action: Amphotericin B binds to ergosterol in the parasite’s cell membrane, leading to cell death.
  • Side Effects: Liposomal amphotericin B is generally well-tolerated but can cause infusion-related reactions, kidney toxicity, and electrolyte imbalances.

3. Miltefosine

Miltefosine is the first oral drug approved for the treatment of kala-azar. It is effective in treating visceral leishmaniasis, particularly in regions such as South Asia.

  • Dosage: Administered orally at 2.5 mg/kg/day for 28 days.
  • Mechanism of Action: Miltefosine disrupts the parasite’s cell membrane and induces apoptosis (programmed cell death).
  • Side Effects: Common side effects include nausea, vomiting, diarrhea, and elevated liver enzymes. It is contraindicated in pregnant women due to its teratogenic effects.

4. Paromomycin

Paromomycin is an aminoglycoside antibiotic that is used as an alternative treatment for kala-azar, particularly in combination therapy.

  • Dosage: Administered as an intramuscular injection at 15 mg/kg/day for 21 days.
  • Mechanism of Action: Paromomycin disrupts protein synthesis in the Leishmania parasite, leading to its death.
  • Side Effects: Paromomycin can cause ototoxicity (hearing loss) and nephrotoxicity (kidney damage).

5. Combination Therapy

In some regions, particularly where drug resistance is a concern, combination therapy is used to improve treatment outcomes and reduce the risk of relapse. Common combinations include:

  • Miltefosine and Paromomycin
  • Sodium Stibogluconate and Paromomycin
  • Liposomal Amphotericin B and Miltefosine

Treatment of Complications

In addition to antileishmanial therapy, supportive care is often required to manage the complications of kala-azar, such as anemia, secondary infections, and nutritional deficiencies.

1. Blood Transfusions

In cases of severe anemia, blood transfusions may be necessary to restore hemoglobin levels and improve oxygen delivery to tissues.

2. Antibiotics

Secondary bacterial infections, such as pneumonia or skin infections, are common in patients with kala-azar. Antibiotic therapy may be needed to treat these infections and prevent sepsis.

3. Nutritional Support

Nutritional support is critical for patients with kala-azar, particularly those who are malnourished or have experienced significant weight loss. High-calorie, nutrient-dense foods and supplements can help patients regain strength and improve their immune response.

Treatment Duration and Monitoring

The duration of treatment for kala-azar varies depending on the drug used, the severity of the disease, and the patient’s response to therapy. Most treatment regimens last between 21 and 30 days. After completing treatment, patients should be monitored for signs of relapse, which can occur in some cases, particularly in immunocompromised individuals.

Common Medications for Kala-azar

Several medications are commonly used to treat kala-azar, depending on the region, drug availability, and the patient’s condition. The most widely used medications include:

1. Sodium Stibogluconate

Sodium stibogluconate is an antimonial drug that has been used for decades to treat kala-azar. It remains the first-line treatment in some regions, although resistance has emerged in certain areas.

  • How It Works: Sodium stibogluconate disrupts the energy metabolism of the Leishmania parasite, leading to its death.
  • Side Effects: Significant side effects include pancreatitis, liver toxicity, cardiac arrhythmias, and bone marrow suppression.

2. Liposomal Amphotericin B

Liposomal amphotericin B is considered the gold standard for treating kala-azar due to its high efficacy and lower toxicity compared to other treatments.

  • How It Works: Liposomal amphotericin B binds to ergosterol in the parasite’s cell membrane, causing cell death.
  • Side Effects: Infusion-related reactions, kidney toxicity, and electrolyte imbalances can occur, but the drug is generally well-tolerated.

3. Miltefosine

Miltefosine is the only oral drug available for treating kala-azar and is commonly used in regions such as South Asia.

  • How It Works: Miltefosine disrupts the parasite’s cell membrane and induces apoptosis.
  • Side Effects: Common side effects include nausea, vomiting, and liver enzyme elevation. It is contraindicated in pregnant women due to its teratogenic effects.

4. Paromomycin

Paromomycin is an aminoglycoside antibiotic used in combination therapy for kala-azar.

  • How It Works: Paromomycin disrupts protein synthesis in the parasite, leading to its death.
  • Side Effects: Ototoxicity and nephrotoxicity are potential side effects.

5. Combination Therapy

Combination therapy is used in areas where drug resistance is a concern. The most common combinations are:

  • Miltefosine and Paromomycin
  • Sodium Stibogluconate and Paromomycin
  • Liposomal Amphotericin B and Miltefosine

Where is Kala-azar Most Prevalent?

Kala-azar is endemic in parts of tropical and subtropical regions, particularly in areas with poor socioeconomic conditions and limited access to healthcare. The disease disproportionately affects people living in rural areas with high levels of poverty and malnutrition.

Geographic Distribution

1. South Asia

South Asia, particularly India, Nepal, and Bangladesh, is home to a significant portion of the global burden of kala-azar. In India, the disease is most prevalent in the states of Bihar, Jharkhand, and Uttar Pradesh. Efforts to control the disease in these regions have led to a substantial reduction in the number of cases, but kala-azar remains a significant public health challenge.

2. East Africa

East Africa is another major hotspot for kala-azar, with Sudan, South Sudan, Ethiopia, and Kenya being the most affected countries. The disease is particularly prevalent in remote, rural areas where access to healthcare is limited. Conflict and displacement in these regions have further complicated efforts to control the disease.

3. South America

In South America, Brazil is the most affected country, particularly in the northeastern and Amazon regions. Other countries, such as Paraguay, Venezuela, and Bolivia, also report cases of kala-azar, although at lower rates.

Prevention of Kala-azar

Preventing kala-azar involves reducing the transmission of the Leishmania parasite by controlling the sandfly vector, protecting people from sandfly bites, and ensuring early diagnosis and treatment of infected individuals to prevent further spread of the disease.

Vector Control

Controlling the sandfly population is a key strategy for reducing the transmission of kala-azar.

1. Insecticide Spraying

Indoor residual spraying of insecticides in homes and animal shelters is an effective way to kill sandflies and reduce the risk of transmission. Regular spraying in endemic areas, particularly before the sandfly breeding season, can significantly reduce the incidence of kala-azar.

2. Insecticide-Treated Nets

Sleeping under insecticide-treated bed nets can protect individuals from sandfly bites, particularly in regions where sandflies are most active at night. These nets can also help reduce the overall sandfly population by killing sandflies that come into contact with the treated material.

3. Environmental Management

Environmental management strategies, such as clearing vegetation around homes, filling in cracks in walls, and improving housing conditions, can help reduce sandfly breeding sites. These measures are particularly important in rural areas where sandflies thrive in dark, humid environments.

Personal Protection

In addition to vector control, individuals can take personal protective measures to reduce the risk of sandfly bites.

1. Wearing Protective Clothing

Wearing long-sleeved clothing and pants, particularly in the evening and at night when sandflies are most active, can reduce the risk of bites. Light-colored clothing is less attractive to sandflies.

2. Using Insect Repellents

Insect repellents containing DEET, picaridin, or other effective ingredients can help protect against sandfly bites. Repellents should be applied to exposed skin, particularly in areas where sandflies are prevalent.

3. Avoiding Sandfly Habitats

Sandflies are most active in dark, humid environments, such as forests, caves, and areas with dense vegetation. Avoiding these habitats, particularly during peak sandfly activity periods (dusk to dawn), can reduce the risk of exposure.

Early Diagnosis and Treatment

Early diagnosis and treatment of kala-azar are essential to prevent severe complications and reduce mortality. In endemic areas, healthcare workers should be trained to recognize the symptoms of kala-azar and provide prompt treatment.

1. Active Case Detection

Active case detection involves screening individuals in endemic areas for symptoms of kala-azar and testing them for the disease. This strategy helps identify cases early and prevents the spread of the disease to others.

2. Access to Treatment

Improving access to antileishmanial treatment in endemic areas is critical for controlling kala-azar. Ensuring that patients receive appropriate and timely treatment can prevent complications, reduce mortality, and limit transmission of the parasite.

Public Health Education

Public health education is a key component of kala-azar prevention efforts. Raising awareness about the disease, its symptoms, and prevention strategies can empower communities to take action to protect themselves from infection.

1. Community Education Campaigns

Community education campaigns can provide information on how to recognize the symptoms of kala-azar, the importance of seeking early treatment, and how to protect against sandfly bites. These campaigns should target high-risk populations, particularly in rural areas.

2. Training Healthcare Workers

Healthcare workers in endemic regions should be trained to diagnose kala-azar accurately and provide appropriate treatment. Training programs can improve the capacity of local health systems to manage the disease effectively.

You may also like...